Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Jacquin, S ^a,c   Rincheval, V ^b   Mignotte, B ^b   Richard, S ^c   Humbert, M ^a   Mercier, O ^a   Londono Vallejo A ^d   Fadel, E ^a   Eddahibi, S ^c  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCROTALINE; PIFITHRIN ALPHA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; BENZOTHIAZOLE DERIVATIVE; PIFITHRIN; TOLUENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; BIOACCUMULATION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INACTIVATION; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG ALVEOLUS MACROPHAGE; LUNG ARTERY PRESSURE; MALE; MTT ASSAY; NONHUMAN; PATHOGENESIS; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; RAT; RAT MODEL; SMOOTH MUSCLE FIBER; TUNEL ASSAY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; WISTAR RAT;

ANIMALIA; RATTUS;

ANIMALS; APOPTOSIS; BENZOTHIAZOLES; CELL PROLIFERATION; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; RATS; RATS, WISTAR; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938718311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131940     Document Type: Article

References (22)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-54. doi: 10.1016/j.jacc.2009.04.012 PMID: 19555858
2. Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122: 4306-4313. doi: 10.1172/JCI60658 PMID: 23202738
3. Archer SL, Weir EK, Wilkins MR (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121: 2045-2066. doi: 10.1161/CIRCULATIONAHA.108.847707 PMID: 20458021
4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S. PMID: 15194174
5. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113: 1857-1864. PMID: 16606791
6. Sakao S, Tatsumi K (2011) Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol 147: 4-12. doi: 10.1016/j.ijcard.2010.07.003 PMID: 20692712
7. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, et al. (2008) The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 558-564. doi: 10.1164/rccm.200709-1369PP PMID: 18556624
8. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. (1998) Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225S-230S. PMID: 9741573
9. Adnot S, Eddahibi S (2007) Lessons from oncology to understand and treat pulmonary hypertension. Int J Clin Pract Suppl: 19-25.
10. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479-1491. PMID: 15931388
11. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. (2008) Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570-578. PMID: 18083891
12. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. PMID: 9039259
13. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310. PMID: 11099028
14. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, et al. (2011) p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 300: L753-761. doi: 10.1152/ajplung.00286.2010 PMID: 21335523
15. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. PMID: 14704432
16. Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, et al. (2013) Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation 127: 1664-1676. doi: 10.1161/CIRCULATIONAHA.113.002434 PMID: 23513067
17. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, et al. (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150. PMID: 11602621
18. Meyrick B, Gamble W, Reid L (1980) Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol 239: H692-702. PMID: 6449154
19. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. PMID: 9153395
20. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923. PMID: 17128209
21. Rosenberg HC, Rabinovitch M (1988) Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 255: H1484-1491. PMID: 3144186
22. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737. PMID: 10481009